IP Library Granted Patent US 7,858,583
Granted Patent B2
US 7,858,583 · App. 12/272,554 · Granted Dec 28, 2010

Process for purifying glycopeptide phosphonate derivatives

Assignee: Theravance, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,858,583
App. No.
12/272,554
Granted
Dec 28, 2010
Kind
B2
Abstract

Disclosed are methods of purifying glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups that are useful as antibacterial agents. The methods include contacting a solution of the glycopeptide derivatives with a polystyrene-containing resin, eluting the resin with an aqueous solution, and isolating the purified glycopeptide derivative.

Claims (11)

1. A composition comprising:

(a) a compound of the formula:

or a salt thereof;

(b) a polystyrene divinyl benzene resin; and

(c) an acidified aqueous solution comprising a polar organic solvent selected from methanol, ethanol, isopropyl alcohol and acetonitrile; wherein the acidified aqueous solution contains acetic acid or hydrochloric acid.

2. The composition of claim 1 , wherein the polar organic solvent is ethanol.

3. The composition of claim 1 , wherein the polar organic solvent is acetonitrile.

4. The composition of claim 1 , wherein the acidified aqueous solution contains acetic acid.

5. The composition of claim 1 , wherein the acidified aqueous solution contains hydrochloric acid.

6. The composition of claim 1 , wherein the polystyrene divinyl benzene resin has a pore size of from about 50 Å to about 1000 Å.

7. The composition of claim 1 , wherein the polystyrene divinyl benzene resin has a particle bead size in the range of between about 20 μm to about 800 μm.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2018
From: THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC
To: CUMBERLAND PHARMACEUTICALS INC.
Reel/Frame 047909/0853 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2014
From: THERAVANCE, INC.
To: THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC
Reel/Frame 033179/0897 →
Continuity (5)
Continuation 1197760500 · Oct 25, 2007
Continuation 1130174000 · Dec 13, 2005
Continuation 1022667600 · Aug 23, 2002
Provisional Application 6031471200 · Aug 24, 2001
Related Publication 20090215673A1 · Aug 27, 2009